Protocols
ABBVIE-M22-947 Phase I OPEN TO ACCRUAL
A Dose Escalation and Expansion Study of AbbVie's Compound in Combination with Anti-Cancer Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
BEIGENE-BGB-11417-105 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and t(11;14)
COMPUGEN-CPG-02-101 Phase I OPEN TO ACCRUAL
A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies
ICHNOS-ISB-1442-101 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma